SCHEMBL2415708

SCHEMBL2415708

O=C(Nc1ccc(O)cc1)c1ccc(F)cc1

nearest known ligand 0.76

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 1/20 0.76
MITF O75030 1/20 0.73
MEN1 O00255 4/20 0.72
KMT2A Q03164 4/20 0.72
POLB P06746 2/20 0.72
TDP1 Q9NUW8 1/20 0.72
RAB9A P51151 4/20 0.70
NPC1 O15118 3/20 0.70
SNCA P37840 2/20 0.70
ATM Q13315 1/20 0.67
DEGS1 O15121 1/20 0.64
NQO2 P16083 2/20 0.61
HTT P42858 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
AURKA O14965 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4491689 1.00 PTPN1 (0.76) PTPN1MITFMEN1KMT2APOLB
SCHEMBL20284430 0.95 PTPN1 (0.86) PTPN1MITFMEN1KMT2APOLB
SCHEMBL10684470 0.92 PTPN1 (0.88) PTPN1MITFMEN1KMT2APOLB
SCHEMBL8420639 0.90 DEGS1 (0.75) PTPN1MEN1KMT2APOLBTDP1
SCHEMBL900928 0.90 DEGS1 (0.75) PTPN1MEN1KMT2APOLBTDP1
SCHEMBL899585 0.90 DEGS1 (0.75) PTPN1MEN1KMT2APOLBTDP1
SCHEMBL8768807 0.86 MEN1 (0.86) PTPN1MITFMEN1KMT2APOLB
SCHEMBL8770854 0.86 PTPN1 (0.79) PTPN1MITFMEN1KMT2APOLB
SCHEMBL18938397 0.86 NPC1 (0.77) PTPN1MITFMEN1KMT2APOLB
SCHEMBL3639776 0.85 MITF (1.00) PTPN1MITFMEN1KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4055007-A1 PROSTAGLANDIN ANALOGS AND USES THEREOF Lifex Biolabs, Inc. (US) 2022-09-14 EP disclosed
US-20210139435-A1 PROSTAGLANDIN ANALOGS AND USES THEREOF Lifex Biolabs, Inc. 2021-05-13 US disclosed
US-8026370-B2 Peroxisome proliferator antagonist; hyperlipemia agents; arteriosclerosis; antiischemic agents MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-09-27 US disclosed
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof MITSUBISHI PHAMA CORPORATION (JP) 2008-07-10 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors BROOKS DAWN A 2007-11-29 US disclosed
CN-101068797-A Carboxylic acid derivative containing thiazole ring and pharmaceutical use thereof MITSUBISHI PHARMA CORP (JP) 2007-11-07 CN disclosed
EP-1816128-A1 CARBOXYLIC ACID DERIVATIVE CONTAINING THIAZOLE RING AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2007-08-08 EP disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-7192982-B2 Modulators of peroxisome proliferator activated receptors LIGAND PHARMACEUTICALS, INC. (US) 2007-03-20 US disclosed
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors ELI LILLY AND COMPANY 2005-01-27 US disclosed
CN-1543451-A Receptor modulators activated by peroxizonal proliferators (ppar) 2004-11-03 CN disclosed
EP-1392637-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2004-03-03 EP disclosed
WO-2002100813-A2 MODULATORS OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS ELI LILLY AND COMPANY (US) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167307-A1 Carboxylic Acid Derivative Containing Thiazole Ring and Pharmaceutical Use Thereof PPARA, PPARD, PPARG PTPN1 1803/4885MITF 1454/4885MEN1 4667/4885
US-20210139435-A1 PROSTAGLANDIN ANALOGS AND USES THEREOF PTGDR, NR3C1, PTGIR PTPN1 1903/4885MITF 463/4885MEN1 3410/4885
US-20050020684-A1 Modulators of peroxisome proliferator activated receptors NCOA4, PPARG, PPARA PTPN1 1824/4885MITF 3436/4885MEN1 4860/4885
US-20070276138-A1 Modulators of peroxisome proliferator activated receptors PPARG, NCOA4, PPARA PTPN1 1691/4885MITF 3231/4885MEN1 4857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.